Schering Aktiengesellschaft

Institut Fur Diagnostikforschung Gmbh

Shering Ag

Schering Aktiengessellschaft

Institut Fue Diagnostikforschung Gmbh

Jurgen Conrad

Heinz Gries

Heribert Schmitt-Willich

Hanns-Joachim Weinmann

Ulrich Niedballa

Bernd Raduchel

Hubert Vogler

Julius Deutsch

Johannes Platzek

Gabriele Schuhmann-Giampieri

Wolfgang Ebert

Erich Klieger

Mary Lee-Vaupel

Ulrich Speck

Franz Karl Maier

Reinhard Neumeier

Josef Gaida

Ludger Dinkelborg

Franz-Josef Renneke

Wolfgang Muetzel

Wolfgang Kramp

Gabrielle Schumann-Giampieri

Jens Schneider-Mergener

Christoph Stephan Hilger

Christoph-Stephan Higler

Cornelius Frommel

Sebastian Erber

Gabriele Kuttner

Wolfgang Hohne

Reinhard Malin

Hans Martin Schier

Renate Steinbrecher

Sabina Hofmann

These invention relates to metal-complexing, cysteine-free peptides which may be coupled to an organ-specific probe directly or via a linker and are thus enriched as conjugates specifically in tumors, organs, tissues or centers of inflammation. The organ-specific probes used are, for example, antibodies or part-sequences of antibodies against tumor-associated antigens, e.g. the carcino-embryonal antigen (CEA, which are thus specifically enriched in tumors. The invention also relates to processes for producing the metal-complexing cysteine-free peptides and their conjugates. The present invention also relates to the use of the conjugates as components of a kit for in vivo diagnosis or in vivo therapy and radio-pharmaceuticals containing these conjugates together with radio-isotopes. The organ-specific conjugates are used to image tumors, organs or centers of inflammation.

Metal-binding cystein-free peptides for diagnostic and therapeutical purposes, methods for their production, and pharmaceuticals containing these compounds

1,4,7,10-tetraazacyclododecane derivatives, their use, pharmaceutical

Compounds of general formula I ##STR1## wherein Z.sup.1, Z.sup.2, X, R.sup.2 and R.sup.3 are as herein defined, are valuable pharmaceutical agents. In particular, the compounds are useful as contrast agents in NMR diagnosis.

DTPA monoamides, pharmaceutical agents containing these compounds, their

3-,8-substituted deuteroporphyrin derivatives, pharmaceutical agents

Chelate compounds of general formula I ##STR1## wherein X is a hydrogen atom and/or a metal ion equivalent of an element of atomic numbers 21-29, 31, 32, 37-40, 42-44, 49 or 57-83, and

DTPA monoamides for MRI

Compounds of a general Formula I ##STR1## wherein Z.sup.1 and Z.sup.2 in each case independently mean the residue

Derivatized DTPA complexes, pharmaceutical agents containing these

1. Compounds of general Formula I ##STR1## wherein n and m in each case mean the numbers 0, 1, 2, 3 and 4,

Substituted complexing agents, complexes, and complex salts, processes

Polymers comprising a ligand containing a carboxylic acid group, optionally at least one ion of an element of the atomic numbers 21-29, 42, 44 or 57-83 as well as optionally cations of inorganic and/or organic bases, amino acids or amino acid amides are valuable complexing agents and complexes for diagnosis.

Polymer-bonded complexing agents and pharmaceutical agents containing

Polymer-bonded complexing agents, their complexes and conjugates,

Meso-tetraphenylporphyrin complex compounds, process for their

Complex compounds of general Formula I ##STR1## wherein X is a hydrogen atom and/or a metal ion equivalent of at least one element of atomic numbers 21-29, 42, 44 or 58-70, with at least two of the substituents X representing a metal ion equivalent, and

Use of amide complex compounds

Porphyrin complex compounds, consisting of a mesotetraphenylporphyrin ligand, optionally at least one ion of an element with atomic numbers 13, 21, 32, 37-39, 42-44, 49, 50 or 57-83 as well as optionally cations of inorganic and/or organic bases, amino acids or amino acid amides, are valuable diagnostic and therapeutic agents.

Mesotetraphenylporphyrin complex compounds, process for their production

Porphyrin complex compounds consisting of at least one porphyrin ligand, optionally at least one ion of an element of atomic numbers 5, 13, 21-32, 37-39, 42-44, 49, 50 or 57-83 as well as optionally cations of inorganic and/or organic bases, amino acids or amino acid amides, are valuable diagnostic media and therapeutic agents.

13,17-propionic acid and propionic acid derivative substituted porphyrin

Growing community of inventors

Berlin, Germany

Jurgen Conrad